Ulipristal acetate 5 mg for uterine fibroids not to be used during ongoing review of liver injury risk
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
|
| Active substance |
ulipristal acetate
|
| Therapeutic area (MeSH) |
Leiomyoma
|
| Procedure number |
EMEA/H/A-31/1496
|
| Regulatory outcome |
Suspension
|
| DHPC type |
Interim measures
|
| Referral name |
Ulipristal acetate 5mg medicinal products
|
| Dissemination date |
23/03/2020
|